A broad spectrum antibiotic belonging to the aminomethylcycline subclass of tetracycline antibiotics.
Approved for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.
The organisms responsible for community acquired pneumonia are usually not confirmed, but S. Pneumoniae and mycoplasma pneumoniae are common pathogens.
Trade name Nuzyra.
Has activity against a broad range of Gram-positive and select Gram-negative pathogens.
Has potent in vitro activity against Gram-positive aerobic bacteria including methicillin-resistant Staphylococcus aureus (MRSA), pencillin-resistant and multi-drug resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus, Acinetobactet species, beta-lactamase positive Hemophilus influenzas, and non- ceftazidine susceptible and non-imipenem susceptible Enterobacteriaceae.
It is not active again Pseudomonas, Proteus, Morganella, or Providential species.
Has antimicrobial activity against common Gram-negative aerobes, some anaerobes, and atypical bacteria such as Legionella and Chlamydia.
It is metabolically stable and neither inhibits nor interacts with metabolizing enzymes or transporters.
Similar to that of other tetracyclines, its mechanism of action is inhibition of bacterial protein synthesis.
It has activity against bacterial strains expressing the two main forms of tetracycline resistance of efflux and ribosomal protection.
An effective treatment in patients with complicated skin and skin structure infections.
Controlled trials comparing omadacycline to linezolid for the treatment of acute bacterial skin and skin structure infections, and comparing omadacycline to moxifloxacin for the treatment of community-acquired bacterial pneumonia showed non inferiority.
Once-daily IV and oral treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults.
Recommended IV loading dose for treatment of community acquired pneumonia and acute bacterial skin and skin structure infections is 200 mg over 60 minutes once or 100 mg over 30 minutes twice a day, followed by maintenance treatment with 100 mg IV once daily: subsequently switching to 300 mg orally daily.
For acute bacterial skin and skin structure infections an all or regimen is approved with a loading dose of 450 mg once daily for two days followed by maintenance of 300 mg once daily.